CSPC Pharmaceutical

石药集团

1093.HKpharmaShijiazhuang

Trials 50

Subs 0

People 0

Links 1

Executive Summary

CSPC Pharmaceutical is a major Chinese integrated pharmaceutical company with strong domestic market presence and growing international ambitions. The company has demonstrated active deal-making posture with focus on innovative drugs and biosimilars, particularly in oncology and cardiovascular therapeutics. With clear BIOSECURE status, CSPC presents lower regulatory risk for US partnerships, though limited public pipeline visibility may require deeper due diligence.

Structure: CSPC operates through a traditional Hong Kong holding company structure listed on HKEX, with mainland Chinese operating subsidiaries focused on R&D, manufacturing, and distribution. The structure avoids VIE complications common among Chinese tech companies, providing cleaner ownership for potential partnerships.

Ownership & Shareholder Structure

—

CSPC Pharmaceutical → AstraZeneca

deal_partner

AZ-CSPC $18.5B. Novel lipoprotein disruptor.

Clinical Trials(50 total)

Phase 3

Phase 2

Phase 1

Phase 1, Phase 2

Phase 2, Phase 3

NCT ID	Interventions	Phase	Status	Enrollment
NCT07417735	SYS6010, Investigator's Choice of Chemotherapy (Irinotecan hydrochloride，Paclitaxel，Docetaxel)	Ph.3	NOT YET RECRUITING	436
NCT07442565	SYS6010, Docetaxel	Ph.3	NOT YET RECRUITING	506
NCT07420257	CM326 injection, Placebo of CM326	Ph.3	NOT YET RECRUITING	212
NCT06770257	daunorubicin, cytarabine liposomes, Azacitidine, Venetoclax	Ph.2	WITHDRAWN	0
NCT06562894	SYHX1901, Placebo	Ph.2	NOT YET RECRUITING	156
NCT06958679	SYS6005	Ph.1	RECRUITING	132
NCT07415863	SYS6043	Ph.1, Ph.2	RECRUITING	820
NCT06543966	Aprepitant Injection, Aprepitant Injection Placebo	Ph.3	NOT YET RECRUITING	486
NCT06505395	SYHX2008 injection, Sandostatin LAR@	Ph.2	RECRUITING	90
NCT06525350	Glumetinib tablets, HB1801 (docetaxel, albumin-bound）, Docetaxel	Ph.2	NOT YET RECRUITING	256
NCT06451666	Pilocarpine HCl Ophthalmic Solution, Vehicle	Ph.3	NOT YET RECRUITING	330
NCT06225622	Irinotecan Liposome, Oxaliplatin, 5-FU, LV, Bevacizumab, Cetuximab	Ph.1	RECRUITING	78
NCT06224842	mitoxantrone liposome 16 and azacitidine, mitoxantrone liposome 18 and azacitidine, mitoxantrone liposome 20 and azacitidine	Ph.1, Ph.2	UNKNOWN	30
NCT05774340	CM326, Placebo	Ph.2	UNKNOWN	207
NCT05783557	Clevidipine Butyrate Injectable Emulsion, Cleviprex®	Ph.3	UNKNOWN	398
NCT05761028	CM310, Placebo	Ph.2, Ph.3	RECRUITING	600
NCT05858047	Placebo, SYHX1901	Ph.2	COMPLETED	93
NCT05810103	DP303c	Ph.1	UNKNOWN	12
NCT05625919	Sirolimus for Injection (Albumin Bound)	Ph.1, Ph.2	UNKNOWN	54
NCT05522192	Mitoxantrone liposome, Venetoclax	Ph.1, Ph.2	RECRUITING	70

Showing 20 of 50 trials

Top Publications (by citations)

Complete genome sequence of Lactobacillus plantarum WCFS1.

993 citationsProc Natl Acad Sci U S A2003

Kleerebezem M, Boekhorst J, van Kranenburg R, Molenaar D, Kuipers OP, Leer R, Tarchini R, Peters SA, Sandbrink HM, Fiers MW, Stiekema W, Lankhorst RM, Bron PA, Hoffer SM, Groot MN, Kerkhoven R, de Vries M, Ursing B, de Vos WM, Siezen RJ.

Nanoparticles in the clinic: An update.

976 citationsBioeng Transl Med2019

Anselmo AC, Mitragotri S.

The acetate switch.

897 citationsMicrobiol Mol Biol Rev2005

Wolfe AJ.

ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.

812 citationsJ Clin Oncol2019

Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen L, Stenzl A.

Consequences of bile salt biotransformations by intestinal bacteria.

771 citationsGut Microbes2016

Ridlon JM, Harris SC, Bhowmik S, Kang DJ, Hylemon PB.

Nanoparticles in the clinic.

730 citationsBioeng Transl Med2016

Anselmo AC, Mitragotri S.

Organometallic anticancer compounds.

716 citationsJ Med Chem2011

Gasser G, Ott I, Metzler-Nolte N.

Signal peptide-dependent protein transport in Bacillus subtilis: a genome-based survey of the secretome.

565 citationsMicrobiol Mol Biol Rev2000

Tjalsma H, Bolhuis A, Jongbloed JD, Bron S, van Dijl JM.

Smart nanoparticles for cancer therapy.

426 citationsSignal Transduct Target Ther2023

Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L.

Biological Activities of Essential Oils: From Plant Chemoecology to Traditional Healing Systems.

346 citationsMolecules2017

Sharifi-Rad J, Sureda A, Tenore GC, Daglia M, Sharifi-Rad M, Valussi M, Tundis R, Sharifi-Rad M, Loizzo MR, Ademiluyi AO, Sharifi-Rad R, Ayatollahi SA, Iriti M.

BIOSECURE Risk

low

Company maintains clear BIOSECURE status with no BCC designation, indicating lower immediate regulatory risk for US collaborations

Key Exposures:

•Potential future designation risk given China domicile
•Supply chain dependencies in China
•Technology transfer restrictions

Mitigation: Company likely monitoring regulatory developments but specific mitigation measures not publicly disclosed

BD Intelligence

Pipeline Strength6/10

Deal Readiness7/10

Therapeutic Areas:

oncologycardiovasculardiabetesrespiratory

Recent Deals: Limited recent out-licensing activity disclosed publicly; company appears focused on domestic market expansion and in-licensing from international partners

Approach: Approach through established channels in Hong Kong or international offices; focus on complementary therapeutic areas where CSPC's manufacturing capabilities could add value

Red Flags

⚠Limited public disclosure on pipeline specifics
⚠Potential future BIOSECURE designation risk
⚠Currency and regulatory exposure in China operations

Quick Facts

Key People: 0
Subsidiaries: 0
CDMO/CRO Subs: 0
Genomics Subs: 0
Direct BIOSECURE: 0
Corp Events: 0
Gov-Connected: 0
Clinical Trials: 50
Publications: 10
Drug Molecules: 0
Relationships: 1

Sources & Methodology

Clinical trials data: ClinicalTrials.gov API v2 (50 trials linked to this entity)

SEC BIOSECURE filings: EDGAR EFTS full-text search (850+ filings from 230 companies)

Publications: Europe PMC API (10 publications indexed)

Drug molecules: ChEMBL database (European Bioinformatics Institute)

Financial data: East Money (东方财富) datacenter API / CNINFO (巨潮资讯网)

Corporate structure: Company official filings, HKEX/SSE/SZSE disclosures

Executive profiles: Company official biographies, SEC filings, LinkedIn (where verified)

Data is collected from public sources and updated weekly. Corporate intelligence is verified by a native Mandarin-speaking analyst against Chinese-language primary sources including Tianyancha (天眼查), GSXT (国家企业信用信息公示系统), and CNINFO (巨潮资讯网). This is not financial or legal advice.